A Phase 1 interventional study of LY3502970 and [14C]-LY3502970 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 21 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate how much of the study drug (LY3502970) and the radioactive substance 14C incorporated LY3502970 gets into the bloodstream, how its broken down, and how long it takes the body to get rid of it. The study will last up to approximately 9 weeks for each participant.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received a single oral dose of 1 milligram (mg) LY3502970 followed six hours later by an intravenous (IV) dose of approximately 21 microgram (μg) of LY3502970 radiolabeled with carbon-14 (\[14C\]-LY3502970) containing approximately 800 nanocurie (nCi) radioactivity.
Drug: LY3502970 · Drug: [14C]-LY3502970
Administered orally
Administered IV
Pharmacokinetics (PK): Absolute Bioavailability of LY3502970
Absolute bioavailability of LY3502970, expressed in percentage, was estimated using the AUC(0-∞) values from each individual participant based on IV dosed \[14C\]-LY3502970 compared to oral dosed LY3502970, using formula: \[AUC0-∞(oral) x Dose (IV) divided by AUC0-∞(IV) x Dose (oral)\] x100. The sampling time points from pre-oral dose through 186 hours post-IV dose were used to assess this outcome.
Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose; 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose.
PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma
PK: AUC \[0-∞\] of Total Radioactivity in Plasma.
Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose
PK: AUC [0-∞] of [14C]-LY3502970 in Plasma
PK: AUC \[0-∞\] of \[14C\]-LY3502970 in Plasma.
Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose
PK: AUC [0-∞] of LY3502970 in Plasma
PK: AUC \[0-∞\] of LY3502970 in Plasma.
Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose
PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma
PK: Cmax of Total Radioactivity in Plasma.
Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138 hours post-IV dose
PK: Cmax of [14C]-LY3502970 in Plasma
PK: Cmax of \[14C\]-LY3502970 in Plasma.
Time frame: 0 (immediately after IV dosing), 2, 5, 10, 15 minutes and 0.5, 1, 2, 4, 6, 10, 18, 30, 42, 66, 90, 114, 138, 162, 186 hours post-IV dose
PK: Cmax of LY3502970 in Plasma
PK: Cmax of LY3502970 in Plasma.
Time frame: Pre-oral dose, 0.5, 1, 2, 4, 6, 6.5, 7, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120 hours post-oral dose
| Milestone | LY3502970 + [14C]-LY3502970 |
|---|---|
| Started | 10 |
| Received ly3502970 | 10 |
| Received [14c]-ly3502970 | 10 |
| Completed | 9 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Absolute bioavailability of LY3502970, expressed in percentage, was estimated using the AUC(0-∞) values from each individual participant based on IV dosed \[14C\]-LY3502970 compared to oral dosed LY3502970, using formula: \[AUC0-∞(oral) x Dose (IV) divided by AUC0-∞(IV) x Dose (oral)\] x100. The sampling time points from pre-oral dose through 186 hours post-IV dose were used to assess this outcome.
| Percentage | LY3502970 + [14C]-LY3502970 |
|---|---|
| Pharmacokinetics (PK): Absolute Bioavailability of LY3502970 | 77 ± 27 |
PK: AUC \[0-∞\] of Total Radioactivity in Plasma.
| nanogram equivalent*hour per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: Area Under the Curve Concentration Versus Time Curve From Zero to Infinity (AUC [0-∞]) of Total Radioactivity in Plasma | 3.71 ± 29 |
PK: AUC \[0-∞\] of \[14C\]-LY3502970 in Plasma.
| nanogram equivalent*hour per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: AUC [0-∞] of [14C]-LY3502970 in Plasma | 2.91 ± 19 |
PK: AUC \[0-∞\] of LY3502970 in Plasma.
| nanogram*hour per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: AUC [0-∞] of LY3502970 in Plasma | 108 ± 35 |
PK: Cmax of Total Radioactivity in Plasma.
| nanogram equivalent per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: Maximum Concentration (Cmax) of Total Radioactivity in Plasma | 2.10 ± 59 |
PK: Cmax of \[14C\]-LY3502970 in Plasma.
| nanogram equivalent per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: Cmax of [14C]-LY3502970 in Plasma | 2.08 ± 53 |
PK: Cmax of LY3502970 in Plasma.
| nanogram per milliliter | LY3502970 + [14C]-LY3502970 |
|---|---|
| PK: Cmax of LY3502970 in Plasma | 5.43 ± 42 |
Collected over Baseline through end of the follow-up (Up to Day 19). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LY3502970 + [14C]-LY3502970 | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| Event | LY3502970 + [14C]-LY3502970 |
|---|---|
| Vessel puncture site painGeneral disorders | 1/10 |
| COVID-19Infections and infestations | 1/10 |
| HeadacheNervous system disorders | 1/10 |
All enrolled participants.
| Age, Continuous(years) | LY3502970 + [14C]-LY3502970 |
|---|---|
| Mean | 52.4 ± 13 |
| Sex: Female, Male(Participants) | LY3502970 + [14C]-LY3502970 |
|---|---|
| Female | 5 |
| Male | 5 |
| Ethnicity (NIH/OMB)(Participants) | LY3502970 + [14C]-LY3502970 |
|---|---|
| Hispanic or Latino | 0 |
| Not Hispanic or Latino | 10 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | LY3502970 + [14C]-LY3502970 |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 3 |
| White | 7 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Oct 2023 to primary completion in Jan 2024, 2 months.
Results were first posted in May 2026, 2 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Orforglipron